Wall Street brokerages forecast that Dynavax Technologies Co. (NASDAQ:DVAX) will report earnings of ($0.61) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Dynavax Technologies’ earnings, with the highest EPS estimate coming in at ($0.57) and the lowest estimate coming in at ($0.64). Dynavax Technologies reported earnings of ($0.63) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 3.2%. The firm is scheduled to announce its next quarterly earnings report on Monday, August 5th.

According to Zacks, analysts expect that Dynavax Technologies will report full-year earnings of ($2.33) per share for the current financial year, with EPS estimates ranging from ($2.45) to ($2.18). For the next year, analysts anticipate that the company will report earnings of ($1.74) per share, with EPS estimates ranging from ($2.07) to ($1.55). Zacks’ EPS averages are an average based on a survey of sell-side research analysts that follow Dynavax Technologies.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.67) by $0.05. Dynavax Technologies had a negative return on equity of 190.84% and a negative net margin of 1,156.11%. The business had revenue of $5.77 million during the quarter, compared to analysts’ expectations of $5.95 million. During the same quarter in the prior year, the business earned ($0.63) earnings per share. The company’s quarterly revenue was up 3294.1% compared to the same quarter last year.

Several research analysts have issued reports on the company. William Blair reiterated an “outperform” rating on shares of Dynavax Technologies in a research report on Thursday, May 9th. Royal Bank of Canada cut their price objective on Dynavax Technologies to $13.00 and set an “outperform” rating for the company in a research report on Friday. Zacks Investment Research cut Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Thursday, March 28th. ValuEngine cut Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $28.00 price objective (down previously from $32.00) on shares of Dynavax Technologies in a research report on Tuesday, February 26th. Three research analysts have rated the stock with a sell rating and four have given a buy rating to the company. Dynavax Technologies has an average rating of “Hold” and a consensus price target of $23.67.

Shares of Dynavax Technologies stock traded down $0.57 during trading hours on Friday, hitting $5.78. 5,268,048 shares of the company were exchanged, compared to its average volume of 1,101,828. Dynavax Technologies has a 1 year low of $5.12 and a 1 year high of $17.05. The company has a debt-to-equity ratio of 4.88, a current ratio of 5.27 and a quick ratio of 4.61. The stock has a market capitalization of $376.07 million, a PE ratio of -2.27 and a beta of 0.60.

In other Dynavax Technologies news, SVP Robert Coffman sold 63,202 shares of the company’s stock in a transaction on Thursday, February 28th. The stock was sold at an average price of $9.03, for a total value of $570,714.06. Following the sale, the senior vice president now owns 86,268 shares of the company’s stock, valued at $779,000.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP David Louis Johnson sold 20,765 shares of the company’s stock in a transaction on Thursday, February 28th. The shares were sold at an average price of $9.03, for a total value of $187,507.95. Following the completion of the sale, the vice president now directly owns 52,786 shares in the company, valued at approximately $476,657.58. The disclosure for this sale can be found here. Insiders sold 119,411 shares of company stock valued at $1,075,091 in the last quarter. 3.47% of the stock is currently owned by company insiders.

Institutional investors have recently bought and sold shares of the business. Advisor Group Inc. grew its holdings in Dynavax Technologies by 515.3% in the fourth quarter. Advisor Group Inc. now owns 4,473 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 3,746 shares during the last quarter. Quantamental Technologies LLC acquired a new stake in Dynavax Technologies in the first quarter valued at $62,000. M&T Bank Corp acquired a new stake in Dynavax Technologies in the first quarter valued at $78,000. Jefferies Group LLC grew its holdings in Dynavax Technologies by 27.7% in the first quarter. Jefferies Group LLC now owns 12,900 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 2,800 shares during the last quarter. Finally, BNP Paribas Arbitrage SA grew its holdings in Dynavax Technologies by 56,326.1% in the first quarter. BNP Paribas Arbitrage SA now owns 12,978 shares of the biopharmaceutical company’s stock valued at $95,000 after purchasing an additional 12,955 shares during the last quarter. 85.78% of the stock is currently owned by institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

Recommended Story: The role of implied volatility with call option volume

Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.